Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Aromatase inhibitors associated musculoskeletal disorders and bone fractures in postmenopausal breast cancer patients: a result from Chinese population.

Xu L, Wang J, Xue DD, He W.

Med Oncol. 2014 Sep;31(9):128. doi: 10.1007/s12032-014-0128-z. Epub 2014 Jul 24.

PMID:
25056205
2.

Aromatase inhibitor-related musculoskeletal symptoms: is preventing osteoporosis the key to eliminating these symptoms?

Muslimani AA, Spiro TP, Chaudhry AA, Taylor HC, Jaiyesimi I, Daw HA.

Clin Breast Cancer. 2009 Feb;9(1):34-8. doi: 10.3816/CBC.2009.n.006.

PMID:
19299238
3.

Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors.

Mincey BA, Duh MS, Thomas SK, Moyneur E, Marynchencko M, Boyce SP, Mallett D, Perez EA.

Clin Breast Cancer. 2006 Jun;7(2):127-32.

PMID:
16800971
4.

Fracture incidence in pre- and postmenopausal women after completion of adjuvant hormonal therapy for breast cancer.

Koopal C, Janssen-Heijnen ML, van de Wouw AJ, van den Bergh JP.

Breast. 2015 Apr;24(2):153-8. doi: 10.1016/j.breast.2014.12.008. Epub 2015 Jan 22.

PMID:
25618224
5.

Aromatase inhibitors alone or sequentially combined with tamoxifen in postmenopausal early breast cancer compared with tamoxifen or placebo - Meta-analyses on efficacy and adverse events based on randomized clinical trials.

Rydén L, Heibert Arnlind M, Vitols S, Höistad M, Ahlgren J.

Breast. 2016 Apr;26:106-14. doi: 10.1016/j.breast.2016.01.006. Epub 2016 Feb 18. Review.

PMID:
27017249
6.

Systematic review of bone health in older women treated with aromatase inhibitors for early-stage breast cancer.

Becker T, Lipscombe L, Narod S, Simmons C, Anderson GM, Rochon PA.

J Am Geriatr Soc. 2012 Sep;60(9):1761-7. doi: 10.1111/j.1532-5415.2012.04107.x. Review.

PMID:
22985145
7.

Indications of clinical and genetic predictors for aromatase inhibitors related musculoskeletal adverse events in Chinese Han women with breast cancer.

Wang J, Lu K, Song Y, Xie L, Zhao S, Wang Y, Sun W, Liu L, Zhao H, Tang D, Ma W, Pan B, Xuan Q, Liu H, Zhang Q.

PLoS One. 2013 Jul 19;8(7):e68798. doi: 10.1371/journal.pone.0068798. Print 2013.

8.

Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study.

Mieog JS, Morden JP, Bliss JM, Coombes RC, van de Velde CJ; IES Steering Committee.

Lancet Oncol. 2012 Apr;13(4):420-32. doi: 10.1016/S1470-2045(11)70328-X. Epub 2012 Jan 20.

PMID:
22265698
10.

Risk of myocardial infarction, stroke, and fracture in a cohort of community-based breast cancer patients.

Ligibel JA, James O'Malley A, Fisher M, Daniel GW, Winer EP, Keating NL.

Breast Cancer Res Treat. 2012 Jan;131(2):589-97. doi: 10.1007/s10549-011-1754-1. Epub 2011 Sep 1.

PMID:
21881937
11.

Impact of aromatase inhibitor treatment on vertebral morphology and bone mineral density in postmenopausal women with breast cancer.

Villa P, Lassandro AP, Amar ID, Vacca L, Moruzzi MC, Ferrandina G, Terribile D, Masetti R, Scambia G.

Menopause. 2016 Jan;23(1):33-9. doi: 10.1097/GME.0000000000000515.

PMID:
26308233
12.

Clinical review: Effect of endocrine therapies on bone in breast cancer patients.

Santen RJ.

J Clin Endocrinol Metab. 2011 Feb;96(2):308-19. doi: 10.1210/jc.2010-1679. Epub 2010 Dec 8. Review.

PMID:
21147884
13.

Postmenopausal women with hormone receptor-positive breast cancer: balancing benefit and toxicity from aromatase inhibitors.

Ingle JN.

Breast. 2013 Aug;22 Suppl 2:S180-3. doi: 10.1016/j.breast.2013.07.035. Review.

PMID:
24074784
14.

Adverse events and bone health during anastrozole therapy in postmenopausal Japanese breast cancer patients.

Sagara Y, Kosha S, Baba S, Dokiya F, Tamada S, Sagara Y, Matsuyama Y, Ohi Y, Ando M, Rai Y, Sagara Y, Douchi T.

Breast Cancer. 2010 Jul;17(3):212-7. doi: 10.1007/s12282-009-0135-7. Epub 2009 Jun 13.

PMID:
19526308
15.

Fracture risk and adjuvant hormonal therapy among a population-based cohort of older female breast cancer patients.

Neuner JM, Yen TW, Sparapani RA, Laud PW, Nattinger AB.

Osteoporos Int. 2011 Nov;22(11):2847-55. doi: 10.1007/s00198-010-1493-x. Epub 2010 Dec 18.

16.

Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.

Gibson LJ, Dawson C, Lawrence DH, Bliss JM.

Cochrane Database Syst Rev. 2007 Jan 24;(1):CD003370. Review. Update in: Cochrane Database Syst Rev. 2009;(4):CD003370.

PMID:
17253488
17.

Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper.

Rizzoli R, Body JJ, DeCensi A, Reginster JY, Piscitelli P, Brandi ML; European Society for Clinical and Economical aspects of Osteoporosis and Osteoarthritis (ESCEO).

Osteoporos Int. 2012 Nov;23(11):2567-76. doi: 10.1007/s00198-011-1870-0. Epub 2012 Jan 20. Erratum in: Osteoporos Int. 2012 Nov;23(11):2577. De Censi, A [corrected to DeCensi, A].

PMID:
22270857
18.
19.

Health-related quality of life of postmenopausal Chinese women with hormone receptor-positive early breast cancer during treatment with adjuvant aromatase inhibitors: a prospective, multicenter, non-interventional study.

Cao A, Zhang J, Liu X, Wu W, Liu Y, Fan Z, Zhang A, Zhou T, Fu P, Wang S, Ouyang Q, Tang J, Jiang H, Zhang X, Pang D, He J, Shi L, Wang X, Sheng Y, Mao D, Shao Z.

Health Qual Life Outcomes. 2016 Mar 24;14:51. doi: 10.1186/s12955-016-0446-2.

20.

A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMI.

Lintermans A, Van Asten K, Wildiers H, Laenen A, Paridaens R, Weltens C, Verhaeghe J, Vanderschueren D, Smeets A, Van Limbergen E, Leunen K, Christiaens MR, Neven P.

Breast Cancer Res Treat. 2014 Jul;146(1):109-16. doi: 10.1007/s10549-014-2986-7. Epub 2014 May 11.

PMID:
24816806

Supplemental Content

Support Center